Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 22 Neoplasm Metastasis 15 Carcinoma, Non-Small-Cell Lung 7 Glioblastoma 6 Colorectal Neoplasms 5 Triple Negative Breast Neoplasms 4 Recurrence 4 Ovarian Neoplasms 4 Lymphoma, Mantle-Cell 4 Lymphoma, Follicular 4 Endometrial Neoplasms 4 Brain Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Neoplasms 3 Lymphoma, Large B-Cell, Diffuse 3 Lung Neoplasms 3 Hereditary Sensory and Autonomic Neuropathies 3 Head and Neck Neoplasms 3 Solid Tumors 2 Melanoma 2 Lymphoma 2 Leukemia, Myeloid, Acute 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Esophageal Neoplasms 2 Waldenstrom Macroglobulinemia 1 Unspecified Adult Solid Tumor, Protocol Specific 1 Treatment for Metastatic or Locally Advanced Cervical Cancer 1 Tongue Neoplasms 1

Interventions

Paclitaxel 1 NVP-BKM120 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Non-Small Cell Lunch Cancer × NVP-BKM120 × Clear all

NCT01820325 2018-10-11

BASALT-2

Novartis

Phase 1 Terminated

Non-Small Cell Lunch Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡